Determining the Efficacy of Online Cognitive Behavioural Therapy for Generalized Anxiety Disorder Compared to Pharmaceutical Interventions
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 115
- 试验地点
- 1
- 主要终点
- Change in State Trait Anxiety Level
研究概览
简要总结
Generalized anxiety disorder (GAD) is an extremely prevalent and debilitating mental health disorder. Currently, the gold standard treatment for GAD is cognitive behavioural therapy (CBT) and/or pharmacotherapy. The most common medications used to treat GAD are selective serotonin reuptake inhibitors (SSRIs) and selective norepinephrine reuptake inhibitors (SNRIs). While CBT is a gold standard treatment for GAD, it is costly, time-consuming, and often inaccessible. Fortunately, the electronic delivery of CBT (e-CBT) has emerged as a promising solution to address these barriers. e-CBT has shown to offer comparable results to in-person CBT while improving accessibility for patients and time efficiency for clinicians. The following project aims to investigate the treatment efficacy of e-CBT compared to, and in conjunction with pharmacotherapy for GAD. This study has been designed using a quasi-experimental design to allow patients the freedom to choose which treatment modality they would like to receive. Participants with a diagnosis of GAD will be enrolled in 1 of 3 possible treatment arms: e-CBT, medication, or combination. The e-CBT program will include a 12-week psychotherapy program delivered through the Online Psychotherapy Tool (OPTT), a secure, cloud-based, digital mental health platform. The treatment efficacy of e-CBT will be compared to the treatment efficacy of the medication arm and the combination arm. Conclusions: If e-CBT is shown to either be comparable to medication or that the effects of both treatments are augmented when used in tandem, these findings could have major implications on the mental health care system. e-CBT is a more accessible, and affordable treatment that could increase mental health care capacity by four-folds if proven viable.
详细描述
Methodology Research Design. This study has been designed using a quasi-experimental design to allow patients the freedom to choose which treatment modality they would like to participate in. This research design aims to be naturalistic by mimicking the decisions made by patients and physicians regarding course of treatment and type of pharmacotherapy prescribed within mental health services across Ontario. The treatments provided within the study also aim to replicate evidence-based best practice clinical guidelines for treatment of GAD.
Research Participants. Patients will be referred to the study by primary care physicians within Toronto and Kingston, Ontario. Patients will be referred to the Anxiety Outpatient Clinic at the Hotel Dieu Hospital site of Kingston Health Sciences Centre or the Mood and Anxiety Clinic within the Centre for Addiction and Mental Health (both sites herein referred to as "the clinic"). Upon receiving a referral to the clinic, participants will be contacted by the study's Research Coordinator and asked to indicate their interest (or lack thereof) in the study. If interest is indicated and the study's inclusion criteria are met, the patient will have a study intake appointment scheduled for the same day as their intake appointment at the clinic. To be considered for inclusion within the study, patients must:
- be 18 years of age or older
- have consistent and reliable access to the internet
- be diagnosed with GAD according to the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-V) by a clinician
- meet the criteria for GAD according to the GAD-7 Screener (GAD-7)
- Be competent to consent to participate
- Speak and read English Patients will be deemed ineligible for participation in the study if they are in acute distress.
Allocation of Subjects between Arms of the Study. Subjects will be presented with all three arms of the study within their study intake appointment by the Research Coordinator. After obtaining informed consent, patients will meet with one of the study's psychiatrists during their clinic intake appointment and discuss the recommended treatment plan. In collaboration with the psychiatrist, patients will decide whether or not they would like to begin pharmacotherapy and/or e-CBT treatment.
Criteria for Discontinuation. Patients' participation in the study will be discontinued if they are found to be noncompliant to their treatment. This will be defined as stopping medications all together or reportedly skipping more than two days in a row of medication. Patients will be found noncompliant with e-CBT treatment if they miss more than two weeks of e-CBT sessions or fail to complete weekly homework assignments. Patients' participation within the study will also be halted if they are deemed to be in acute crisis by self-report or the psychiatrist in charge of their care.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18 years of age or older
- •Have consistent and reliable access to the internet
- •Be diagnosed with GAD according to the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-V) by a clinician
- •Meet the criteria for GAD according to the GAD-7 Screener (GAD-7)
- •Be competent to consent to participate
- •Speak and read English
排除标准
- •Patients will be deemed ineligible for participation in the study if they are in acute distress.
研究组 & 干预措施
e-CBT
Weekly sessions of e-CBT through OPTT will consist of approximately 30 slides. Each session is expected to last approximately 50 minutes. The content and format of each weekly online session were designed to mirror live CBT. The slides will highlight a different topic each week and include general information, an overview of skills and homework on that topic. The homework included in each session will be submitted through OPTT and reviewed by the clinicians with personalized feedback provided by clinicians within three days of submission. Weekly homework submission for feedback will be mandatory before being eligible for the next session. Biweekly GAD-7, DASS-42 and Q-LES-SF questionnaires will be completed through OPTT. A second STAI will be completed in the final week of e-CBT treatment.
干预措施: Electronic Cognitive Behavioural Therapy (Behavioral)
Pharmacotherapy
Biweekly meeting with psychiatrist with GAD-7, DASS-42 and Q-LES-SF. Pharmacotherapy class decided according to protocol developed in accordance with Canada's best practice guidelines for GAD treatment. At second appointment, medication will be maintained and optimized, regardless of response. At third appointment, optimized if partial response or switched according to protocol if no response. Partial response is improvement of 20% or more in GAD-7. If switched, 6-week protocol will recommence with new medication. At fourth appointment, dosage optimized if responding well to medication and improvement greater than 50% within primary arm, or 20% if secondary arm, patient will remain on said medication for remainder of 12-week study. If not improving more than 20%, medication switched according to protocol and 6-week protocol will recommence. If primary arm and 20-50% improvement after six weeks on new medication, augmented with olanzapine, risperidone or benzodiazepines.
干预措施: SSRIs/SNRIs (Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors) (Drug)
e-CBT + Pharmacotherapy
Participants will commence both treatments described above simultaneously.
干预措施: SSRIs/SNRIs (Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors) (Drug)
e-CBT + Pharmacotherapy
Participants will commence both treatments described above simultaneously.
干预措施: Electronic Cognitive Behavioural Therapy (Behavioral)
结局指标
主要结局
Change in State Trait Anxiety Level
时间窗: Baseline, week 2, 4, 6, 8, 10, 12, plus 6-month follow-up
State Trait Anxiety Inventory (STAI) - Scale: 1-4 (1 = not at all, 4 = very much)
Change in Quality of Life
时间窗: Baseline, week 2, 4, 6, 8, 10, 12, plus 6-month follow-up
Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-QSF) - Scale: 1-5 (1 = very poor, 5 = very good)
Change in Generalized Anxiety Levels
时间窗: Baseline, week 2, 4, 6, 8, 10, 12, plus 6-month follow-up
Generalized Anxiety Disorder - 7 (GAD-7) - Scale: 0-3 (0 = never, 3 = nearly every day)
Change in Depression and Anxiety Scale
时间窗: Baseline, week 2, 4, 6, 8, 10, 12, plus 6-month follow-up
42-item Depression Anxiety Stress Scales (DASS-42) Scale: 0-3 (0 = not at all, 3 = very much)
次要结局
- Demographics Information(Baseline, week 2, 4, 6, 8, 10, 12, plus 6-month follow-up)
研究者
Dr. Nazanin Alavi
Principal Investigator, Assistant Professor
Queen's University
